March Outlook For Sangamo Therapeutics

Sangamo Therapeutics (SGMO) price action continues to trade within the downward channel that has been in play since September 2018. SGMO has continued to feel the effects of the poor performance in the MPS clinical trials of its proposed medication for the treatment of Hunter's syndrome. We examine the latest price movements in order to get some idea of its performance for the next few weeks.

On March 8, 2019, Sangamo announced an improvement to its critical zinc finger nuclease (ZFN) platform technology; a change which is expected to improve the genome-editing precision of its technology.

Original source

Add comment

Please Sign in to be able to leave comments.